Big Japanese Pharmas Plan R&D Push As Patents Expire
This article was originally published in PharmAsia News
Executive Summary
Japan's largest pharmaceuticals are investing heavily in research and development, chasing their next new drug in advance of expiring patent protection on some of their best-sellers that begins next year. Astellas plans a 6 percent increase despite a decreasing profit this year, Daiichi Sankyo and Eisai see R&D increases of 5 percent, each, and Takeda Pharmaceutical, the largest of the four, plans a 6 percent increase in its R&D budget. All but Eisai have major drugs in Phase III testing, while Eisai looks for something in the field of cancer, thanks to its acquisition of MGI Pharma of the United States. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.